📊 COGT Key Takeaways
Investment Thesis
Cogent Biosciences is in severe financial distress with catastrophic operating losses (-$333.4M) and negative free cash flow (-$266.0M), indicating the company is burning cash rapidly despite having $312.0M in reserves. Revenue has collapsed 65% YoY to just $7.9M, demonstrating fundamental business deterioration that vastly exceeds cash runway sustainability. The combination of massive operating losses, negative margins exceeding -4000%, and severely negative return metrics indicates a company in existential crisis with minimal near-term path to profitability.
COGT Strengths
- Adequate liquidity position with $312.0M in cash and 14.23x current ratio providing near-term operational runway
- Manageable debt-to-equity ratio of 0.35x suggesting moderate leverage relative to equity base
- Positive stockholders equity of $636.4M provides balance sheet cushion against further losses
COGT Risks
- Catastrophic revenue decline of 65% YoY indicates severe business contraction and loss of market traction
- Massive operating losses of -$333.4M with negative FCF of -$266.0M consuming cash reserves at unsustainable rate
- Negative operating margin of -4235% and net margin of -4179% indicate business model is fundamentally broken with no path to profitability visible
- Operating cash burn of -$264.4M annually means current $312.0M cash reserves provide only ~14 months of runway at current burn rate
- Diluted EPS of -$2.16 and worsening 11.3% YoY suggests continued shareholder value destruction
Key Metrics to Watch
- Quarterly revenue trend and stabilization of product sales pipeline
- Operating cash burn rate and cash runway remaining before liquidity crisis
- Operating expenses reduction initiatives and pathway to operating profitability
- Clinical trial progress and regulatory approvals for pipeline assets
- Cash position depletion trajectory relative to quarterly burn rates
COGT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 14.23x current ratio provides a solid financial cushion.
COGT Profitability Ratios
COGT vs Healthcare Sector
How Cogent Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
COGT Balance Sheet & Liquidity
COGT 5-Year Financial Trend
5-Year Trend Summary: Cogent Biosciences, Inc.'s revenue has declined by 19% over the 5-year period, indicating business contraction. The most recent EPS of $-1.94 indicates the company is currently unprofitable.
COGT Growth Metrics (YoY)
COGT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $312.0K | -$6.1M | N/A |
| Q2 2021 | $528.0K | -$6.1M | N/A |
| Q1 2021 | $7.0M | -$6.1M | N/A |
| Q3 2020 | $312.0K | -$6.1M | N/A |
| Q2 2020 | $528.0K | -$6.1M | N/A |
| Q1 2020 | $3.1M | -$6.1M | N/A |
| Q3 2019 | $1.0M | -$6.7M | N/A |
| Q2 2019 | $1.7M | -$6.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
COGT Capital Allocation
COGT SEC Filings
Access official SEC EDGAR filings for Cogent Biosciences, Inc. (CIK: 0001622229)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COGT
What is the AI rating for COGT?
Cogent Biosciences, Inc. (COGT) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are COGT's key strengths?
Adequate liquidity position with $312.0M in cash and 14.23x current ratio providing near-term operational runway. Manageable debt-to-equity ratio of 0.35x suggesting moderate leverage relative to equity base.
What are the risks of investing in COGT?
Catastrophic revenue decline of 65% YoY indicates severe business contraction and loss of market traction. Massive operating losses of -$333.4M with negative FCF of -$266.0M consuming cash reserves at unsustainable rate.
What is COGT's revenue and growth?
Cogent Biosciences, Inc. reported revenue of $7.9M.
Does COGT pay dividends?
Cogent Biosciences, Inc. does not currently pay dividends.
Where can I find COGT SEC filings?
Official SEC filings for Cogent Biosciences, Inc. (CIK: 0001622229) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COGT's EPS?
Cogent Biosciences, Inc. has a diluted EPS of $-2.16.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.